Document:

April
20, 2018

 

Brands
International Corporation

Attn:
Mark Rubinoff, CEO

Via
email 

 

RE:
Amendment #3 for the 12-26-17 Letter of Intent Termination Date to June 1, 2018

 

Dear
Mr. Rubinoff:

 

Novo
Integrated Sciences, Inc., a Nevada corporation (“NIS”) and Brands International Corporation (the parties”)
are parties to the Letter of Intent, dated 12-26-17, as attached hereto as Exhibit A (the “LOI”). Effective January
30, 2018, the parties amended the termination date of the 12-26-17 Letter of Intent to March 20, 2018, as attached hereto as Exhibit
B. Additionally, effective March 16, 2018, the parties amended (“Amendment #2) the termination date of the 12-26-17 Letter
of Intent to April 20, 2018, as attached hereto as Exhibit C.

 

The
purpose of this letter is to amend the LOI (“Amendment #3”) to extend the termination date therein. As we have discussed,
the “Termination Date” for all purposes under the LOI is hereby amended to be June 1, 2018. The LOI, as amended herein,
shall remain in full force and effect.

 

We
continue to look forward to working with you to complete the transaction successfully and expeditiously. If the foregoing correctly
sets forth your understanding, please execute a copy of this Letter in the space set forth below and return to me.

 

	 	Sincerely, 
	 	 	 
	 	Novo Integrated Sciences, Inc.
	 	 	 
	 	By:
    	/s/
    Christopher David
	 	Name:
    	Christopher
    David
	 	Title:
    	President
	 	 	 
	 	Agreed and accepted:
	 	 	 
	 	Brands International Corporation
	 	 	 
	 	By:
    	/s/
    Mark Rubinoff
	 	Name:
    	Mark
    Rubinoff
	 	Title:
    	Chief
    Executive Officer

 

11120
NE 2nd Street, Suite 200 Bellevue, WA 98004 USA

Phone:
(206) 617-9797

www.novointegrated.comAMENDMENT
TO OPTION #21

(Christopher
David, Grant Date June 29, 2015)

 

Dated
as of April 20, 2018

 

THIS
AMENDMENT TO OPTION (the “Amendment”), dated as of the date first set forth above (the “Effective Date”)
is entered into by and between Novo Integrated Sciences Inc., a Nevada corporation (the “Company”) and Christopher
David (the “Holder” or “Optionee”). Each of the Company and Holder may be referred to herein individually
as a “Party” and collectively as the “Parties.”

 

WHEREAS,
on June 29, 2015 the Company issued to Holder an option to purchase 1,500,000 shares of common stock of the Company at an exercise
price of USD$0.16 (the “Option”, “Option #21”) which Option vested on the Grant Date and is currently
set to expire on June 29, 2020 (the “Expiration Date”);

 

WHEREAS,
the Parties now desire to amend the Option #21 Expiration Date, as set forth below; and

 

NOW,
THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties agree as follows:

 

	1.	Amendment.
    The word and number “five (5)” in both Section 1(b) of the Option Agreement and in paragraph 2 of the Certificate
    of Option for Option #21 are hereby amended to read “eight (8)”. This Amendment changes the Expiration Date of
    Option #21 to June 29, 2023.
	 	 
	2.	Miscellaneous.
    This Amendment shall be deemed part of but shall take precedence over and supersede any provisions to the contrary contained
    in the Option. Except as specifically modified hereby, all of the provisions of the Option shall remain in full force and
    effect. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together
    shall be deemed to be one and the same agreement. A signed copy of this Amendment delivered by facsimile, e-mail or other
    means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
    Amendment.

 

[Signatures
appear on following page]

 

    	 	1	 

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of the Effective Date.

 

	 	Novo Integrated Sciences, Inc.
	 	 	 
	(SEAL)	By:	/s/
    Pierre Dalcourt
	 	Name:
    	Pierre
    Dalcourt
	 	Title:
    	Board
    Chairman
	 	 	 
	 	By:
    	/s/
    Michael Gaynor
	 	Name:
    	Michael
    Gaynor
	 	Title:
    	Secretary
    and Director
	 	 	 
	 	Option #21 Optionee
	 	 	 
	 	By:
    	/s/
    Christopher David
	 	Name:
    	Christopher
    David, Individual 

 

    	 	2AMENDMENT
TO OPTION #23

(Christopher
David, Grant Date February 19, 2016)

 

Dated
as of April 20, 2018

 

THIS
AMENDMENT TO OPTION (the “Amendment”), dated as of the date first set forth above (the “Effective Date”)
is entered into by and between Novo Integrated Sciences Inc., a Nevada corporation (the “Company”) and Christopher
David (the “Holder” or “Optionee”). Each of the Company and Holder may be referred to herein individually
as a “Party” and collectively as the “Parties.”

 

WHEREAS,
on February 19, 2016 the Company issued to Holder an option to purchase 500,000 shares of common stock of the Company at an exercise
price of USD$0.16 (the “Option”, “Option #23”) which Option vested on the Grant Date and is currently
set to expire on February 19, 2021 (the “Expiration Date”);

 

WHEREAS,
the Parties now desire to amend the Option #23 Expiration Date, as set forth below; and

 

NOW,
THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties agree as follows:

 

	1.	Amendment.
    The word and number “five (5)” in both Section 1(b) of the Option Agreement and in paragraph 2 of the Certificate
    of Option for Option #23 are hereby amended to read “eight (8)”. This Amendment changes the Expiration Date of
    Option #23 to February 19, 2024.
	 	 
	2.	Miscellaneous.
    This Amendment shall be deemed part of but shall take precedence over and supersede any provisions to the contrary contained
    in the Option. Except as specifically modified hereby, all of the provisions of the Option shall remain in full force and
    effect. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together
    shall be deemed to be one and the same agreement. A signed copy of this Amendment delivered by facsimile, e-mail or other
    means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
    Amendment.

 

[Signatures
appear on following page]

 

    	 	1	 

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of the Effective Date.

 

	 	Novo Integrated Sciences, Inc.
	 	 	 
	(SEAL)	By:	/s/
    Pierre Dalcourt
	 	Name:
    	Pierre
    Dalcourt
	 	Title:
    	Board
    Chairman
	 	 	 
	 	By:
    	/s/
    Michael Gaynor
	 	Name:
    	Michael
    Gaynor
	 	Title:
    	Secretary
    and Director
	 	 	 
	 	Option #21 Optionee 
	 	 	 
	 	By:
    	/s/
    Christopher David
	 	Name:
    	Christopher
    David, Individual

 

    	 	2AMENDMENT
TO OPTION #24

(Christopher
David, Grant Date February 19, 2016)

 

Dated
as of April 20, 2018

 

THIS
AMENDMENT TO OPTION (the “Amendment”), dated as of the date first set forth above (the “Effective Date”)
is entered into by and between Novo Integrated Sciences Inc., a Nevada corporation (the “Company”) and Christopher
David (the “Holder” or “Optionee”), an individual. Each of the Company and Holder may be referred to herein
individually as a “Party” and collectively as the “Parties.”

 

WHEREAS,
on February 19, 2016 the Company issued to Holder an option to purchase 500,000 shares of common stock of the Company at an exercise
price of USD$0.16 (“Option #24” or the “Option”) which Option vested on the 1-year anniversary date of
February 19, 2017 and as defined in Section 1(b) of the Option Agreement, is currently set to expire (the “Expiration Date”)
on February 19, 2022;

 

WHEREAS,
on February 19, 2016 as part of the Option Agreement #24, the Company issued to the Holder a Certificate of Option which in Paragraph
#2 states “The Option expires five (5) years after the date of issue and is exercisable, in whole or in part, at any-time
before they expire” which defines the Expiration Date as February 19, 2021;

 

WHEREAS,
the defined Expiration Date in (a) the Option Agreement, Section 1(b); and (b) the Certificate of Option, paragraph 2, is inconsistent;

 

WHEREAS,
Option Agreement #24, Section 1(b), should state “These Options to purchase the Company common stock must be exercised,
in whole or in part, on or before February 19, 2021”, which represent five (5) years after the Option #24 Grant Date of
February 19, 2016;

 

WHEREAS,
the Parties further desire to amend the option Expiration Date by adding an additional three (3) years to the February 19, 2021
Expiration Date which would provide for an amended Expiration Date of February 19, 2024;

 

WHEREAS,
the Parties now desire to amend the Option, as set forth below; and

 

NOW,
THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties agree as follows:

 

	1.	Amendment
    #1. The Expiration Date of the original Option Agreement #24, as defined in Section 1(b), is hereby amended to read February
    19, 2021;
	 	 
	2.	Amendment
    #2. The Expiration Date noted in Amendment #1 is further extended and amended to add three (3) years which further defines
    the Expiration Date of Option Agreement #24 and its Certificate of Option as February 19, 2024;
	 	 
	3.	Miscellaneous.
    This Amendment shall be deemed part of but shall take precedence over and supersede any provisions to the contrary contained
    in the Option. Except as specifically modified hereby, all of the provisions of the Option shall remain in full force and
    effect. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together
    shall be deemed to be one and the same agreement. A signed copy of this Amendment delivered by facsimile, e-mail or other
    means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
    Amendment.

 

[Signatures
appear on following page]

 

    	 	1	 

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of the Effective Date.

 

	 	Novo Integrated Sciences, Inc.
	 	 	 
	(SEAL)	By:	/s/
    Pierre Dalcourt
	 	Name:
    	Pierre
    Dalcourt
	 	Title:
    	Board
    Chairman
	 	 	 
	 	By:
    	/s/
    Michael Gaynor
	 	Name:
    	Michael
    Gaynor
	 	Title:
    	Secretary
    and Director
	 	 	 
	 	Option #21 Optionee 
	 	 	 
	 	By:
    	/s/
    Christopher David
	 	Name:
    	Christopher
    David, Individual

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]